Categories: News

Sema4 to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

STAMFORD, Conn., Aug. 02, 2021 (GLOBE NEWSWIRE) — Sema4 (Nasdaq: SMFR), a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced it will release financial results for the second quarter of 2021 after the market close on Monday, August 16, 2021. On the same day, Eric Schadt, Ph.D., Founder and Chief Executive Officer of Sema4, and Isaac Ro, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET.

Conference Call Details
The conference call will begin at 4:30 p.m. Eastern Time on Monday, August 16, 2021. Interested parties may access the live teleconference by dialing (844) 631-4065 for domestic callers or (929) 517-0920 for international callers, followed by conference ID: 6887762. A live and archived webcast of the event will be available on the “Events” section of the Sema4 investor relations website at https://ir.sema4.com/.

About Sema4
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.

Investor Relations Contact:
David Deuchler
Gilmartin Group
investors@sema4.com

Media Contact:
Radley Moss
radley.moss@sema4.com

 

Staff

Recent Posts

uMed’s AccessCMD next-generation Cardiometabolic Cohort hits 2000 patient milestone in less than 4 months

Providing researchers with unparalleled opportunity to access novel endpoints LONDON, July 10, 2024 /PRNewswire/ -- Healthcare…

3 hours ago

New research from Dräger Safety : 94% think that Health and Safety legislation needs ‘overhauling’

BLYTH, England, July 10, 2024 /PRNewswire/ --  On the fiftieth anniversary of the main piece…

3 hours ago

Poolbeg Pharma PLC Announces Notification of Major Holdings

LONDON, UNITED KINGDOM / ACCESSWIRE / July 10, 2024 / TR-1: Standard form for notification…

6 hours ago

Evotec and Pfizer Collaborate to Advance Drug Discovery in France

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG,…

6 hours ago

IRLAB Publishes Interim Report for the Period January-June 2024

GOTHENBURG, SWEDEN / ACCESSWIRE / July 10, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July…

6 hours ago

AvodahMed Names Paul Wiley as President

WESTLAKE, Texas, July 9, 2024 /PRNewswire/ -- AvodahMed is pleased to announce the appointment of…

9 hours ago